Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends
DOYLESTOWN, Pa., June 25, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses.
ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation.
"Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies," said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. "We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025."
The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on clinicaltrials.gov.
ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity.
About Metabolics PharmaMetabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit www.metabolicspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625436712/en/
Contacts
Company contact: Richard Larson, M.D., Ph.D.Chief Executive Officer, Chief Medical Officer, and Chairman of the BoardJohn DessoukiChief Financial Officerj.dessouki@metabolicspharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
The CEO building the 'Ikea of factories' wants to democratize semiconductor production
In his 1986 book "Engines of Creation," engineer K. Eric Drexler — often called the godfather of nanotechnology — made a prediction. "The coming era of molecular machines will mean the end of many limits: the limit of scarcity, the limit of slow development, the limit of ignorance enforced by the lack of tools," he wrote. Reading those words a few years later, when he was 16, Matthew Putman started thinking. "Our bodies work as these little micro-machines where you have ribosomes and enzymes and things that are working and replicating and making things all the time, but our factories work the way that they've worked for the last hundred years," Putman told Business Insider he thought at the time. He wondered how a world would look "where you don't have large assembly lines, you don't have smokestacks, you instead just make things so perfectly," he said. Putman became fascinated by the possibilities of machines that are "atomically precise." It wasn't until the recent AI boom, however, that the idea really took off with fabrication plants. Putman, now 50, is the CEO of Brooklyn-based Nanotronics, which he cofounded with his father in 2010. The company started out building microscopes and tools to detect defects in semiconductors, among other materials. Now, it builds small, modular semiconductor manufacturing plants called Cubefabs. While the biggest fabs in the country are often millions of square feet in size, Cubefabs measure anywhere from 25,000 square feet for the smallest units up to about 60,000 square feet for a full-sized fab. They're adaptable, and the company says they can be assembled in under a year in most places on Earth. They're also smart — thanks to the power of AI — so they can self-monitor their production and improve in real time, the company said. And they're relatively cheap, costing a minimum of $30 to $40 million, compared to large fabs that can cost billions to build. With President Donald Trump back in the White House and pledging to reinvigorate US manufacturing, a new opening has emerged for Nanotronics — even as sweeping tariffs challenge companies that produce or depend on semiconductors. Putman says that in the long term, the tariffs will bolster domestic innovation. Tariffs "should be a wake-up call — a push to create something better than what either the US or China has done before," he told BI in a video interview from the Nanotronics headquarters in Brooklyn Navy Yard. "If we get this right, American innovation won't just protect our future — it could help redefine global progress in a way that benefits humanity." Putman says compact, modular factories are exactly that. "Your factory should be incredibly small," Putman said, gesturing to the room behind him. "Eventually, it could be the size of this room." The 'Ikea of factories' Semiconductor manufacturing has surged since the launch of ChatGPT. Global annual revenue for the industry is expected to reach more than $1 trillion by 2030, according to McKinsey & Company. In the US, despite legislation subsidizing domestic semiconductor production, fabs are more expensive to construct and maintain than those built in places like mainland China and Taiwan, McKinsey says. The US also suffers from a shortage of qualified labor, which can delay construction timelines, according to the firm. To attempt to solve some of these issues, Nanotronics teamed up with architecture firm Rogers Partners and engineering firm Arup to design compact factories. Each one runs with 37 people, but Putman says the ideal setup is four factories — about 180 workers total — which allows them to scale up without halting production. "It's like the Ikea of factories," Putman said. The company has raised $182 million to date from firms including Peter Thiel's Founders Fund. Cubefabs can be used to produce chips that span a range of uses across electronics applications, electric vehicles, and photodetectors for cube satellites, Putman said. "The more precise we make things, the more abundance we bring to the world," he said. "The business of making things grow bigger and bigger starts small — molecular small." Building on the foundational research of scientist Philippe Bove — now chief scientist at Nanotronics — the company also uses gallium oxide — a type of semiconductor that can handle more power than traditional materials like silicon — to produce advanced chips. The company plans to have its first installation set up in New York within the next 18 months. "These fabs do not require billions in capital expenditure or large populations of highly trained workers," Putman told BI in a follow-up email. "The vision is that any region — whether in the Global South or the United States — should be able to produce what it needs locally."
Buzz Feed
9 hours ago
- Buzz Feed
This Affordable Moisturizer Is *Incredibly* High Rated
To make the claim that something is 'the best' takes a lot of consideration and research on our part. But, after several praises sung by experts in skincare, tons of positive ratings and some of the most convincing testimonies from people like myself, it's finally time for us to name the original CeraVe Moisturizing Cream as the best moisturizer out there to date. We've given this unassuming and ubiquitous hydrator this title for reasons such as its accessible price point and its truly all-purpose usage that's compatible with even the most sensitive skin types. However, after a dermatologist that we interviewed for a recent story said that the CeraVe cream was one of their 'favorite moisturizers in the entire world,' we knew it was more than just a good product. When board-certified and Texas-based dermatologist Dr. Seemal R. Desai at Innovative Dermatology previously spoke to HuffPost about the best products to manage crepey skin, he explained that moisturizers with thick emollients are what help to replace the ceramides and lipid concentration in the skin, which can help with overall hydration. And like all of the products in CeraVe's line, be it their cult-favorite face washes or targeted serums, this custard-like cream is formulated with three essential ceramides that are fundamental for not just hydration, as mentioned earlier, but for helping to maintain a healthy skin barrier. The formula also contains hyaluronic acid, a tried-and-true humectant that draws moisture into the skin. As a long time sufferer of this common skin condition, I can personally attest to how beneficial the CeraVe Moisturizing Cream has been to managing any irritation, redness and flaking that occurs. In fact, it's the only moisturizer I've continuously used on my body for the past decade because I know it won't exacerbate my incredibly dry and finicky epidermis. Other users of this $14 cream have made similar claims as myself and have even attributed the formula for improving the appearance of fine lines and wrinkles and managing painful skin cracking brought on by the winter elements. Others state that it's the perfect priming layer to wear underneath makeup. As if these assuring words and endless endorsements from dermatologists weren't enough, you can read on to just a few of the promising reviews we found for the CeraVe cream, a product that might be one of the highest rated items we've seen on Amazon. Or grab yourself a long-lasting 8- or 19-ounce tub from any of the above retailers. Get it from Amazon for $13.52+ (available in two sizes).
New York Post
20 hours ago
- New York Post
This common kitchen herb ingredient could help target or slow Alzheimer's
Experts believe they've identified a chemical compound in certain herbs that could help mitigate or prevent Alzheimer's disease — but before anyone makes a run for the spice rack, there are a few catches. In a study published in the journal Antioxidants earlier this year, researchers from the Scripps Research Institute identified a compound called carnosic acid, which is prevalent in rosemary and sage. Advertisement The compound could prove therapeutic for neurodegenerative disorders, including Alzheimer's disease, the experts concluded. Carnosic acid contains 'striking antioxidant [and] anti-inflammatory properties,' the researchers wrote in the findings. Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, based in California, spoke with Fox News Digital about the results. 'In this study, we observed that administering this drug to mice that had advanced Alzheimer's-like disease significantly improved the number of neurons, as well as the number of synapses or connections between the brain cells,' the team said. Advertisement 4 Experts believe they've identified a chemical compound, carnosic acid, in certain herbs like rosemary and sage that could help mitigate or prevent Alzheimer's disease. Brent Hofacker – The experts added, 'It also reduced inflammation that is caused by the current anti-amyloid antibody therapies. We also observed an improvement in the learning and memory behavior of the mice that received the drug.' Banerjee and Lipton also noted that carnosic acid is a 'prodrug,' meaning it's inactive at first — but once it enters the body, it's activated by oxidative and inflammatory stress. 'It specifically targets cells undergoing oxidative and inflammatory stress, without affecting the healthy, normal brain cells,' Banerjee said. Advertisement 'This further makes it a safe option for therapeutics.' The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions, however. Advertisement Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, told Fox News Digital that studies based on a mouse model of Alzheimer's can be helpful but are not conclusive. 4 Experts say carnosic acid could improve inflammation occurring in most aging brains. LIGHTFIELD STUDIOS – 'Models are important in helping us understand the basic biology of the disease, but we need human studies in representative populations for ideas to be fully validated,' Kloske said. 'Therefore, while these are intriguing findings, more research is needed to understand the impacts and outcomes of these compounds on people living with, or at risk for, Alzheimer's.' Cooking sage and rosemary won't provide the full anti-inflammatory effects, Banerjee and Lipton stressed. 4 'We need human studies in representative populations for ideas to be fully validated,' Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, says about the limitations of the information. – 'Critically, one cannot take sufficient herbs safely to produce the same effect as our new drug,' Banerjee said. The study, funded in part by the National Institutes of Health, did have some limitations, the researchers acknowledged. Advertisement Kloske advised that, at this point, 'no one should consume these herbs (or carnosic acid) to prevent or treat Alzheimer's or other cognitive impairment.' 4 According to Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, cooking sage and rosemary won't provide the full anti-inflammatory effects. Ganna – Dr. Lee Murray, a neurologist in Jackson, Tennessee, echoed Kloske's concerns. 'Before patients start incorporating rosemary and sage in every dish they eat, we need to remember these studies are pre-clinical,' Murray told Fox News Digital. Advertisement 'Currently, there is insufficient clinical evidence to recommend rosemary and sage as a standard therapy for Alzheimer's dementia.' Murray, however, said the data 'is encouraging' and opens the door to additional pathways for potential therapeutics. Banerjee said she hopes that 'our drug will start human clinical trials soon.' She added, 'If it proves to be effective, it will be a great new drug for those suffering from Alzheimer's … From the results of our animal studies, we are cautiously optimistic for its success in human clinical trials.'
